Cortecs buys cancer antigen:
This article was originally published in Clinica
Cortecs International has bought the exclusive rights to develop a test for nasopharyngeal cancer from CRCT, the technology transfer arm of the UK Cancer Research Campaign. The technology is based on abnormal response to Epstein-Barr virus infection in people with nasopharyngeal cancer, which is the most common cancer in Chinese men and number two in Chinese women. Cortecs has also acquired an antigen for early detection of TB.